1. Short title This Act may be cited as the Prescription Drug Monitoring Program Best Practices Act of 2018 . 2. Best practice guidelines for using data collected by prescription drug monitoring programs (a) Best practice guidelines The Director of the Bureau of Justice Assistance and the Director of the Centers for Disease Control and Prevention, acting jointly, shall— (1) develop best practice guidelines and potential enhancements to facilitate use of and strengthen prescription drug monitoring programs to identify— (A) unlawful diversion or misuse of controlled substances; and (B) the potential for harmful drug interactions; (2) include in such guidelines— (A) data elements that should be included in proactive, unsolicited reports that are generated and disseminated to authorized users to identify patients at the highest risk for misuse of controlled substances and identify potential inappropriate prescribing trends; and (B) best practices on treatment options for consideration by prescribers (or other health care providers) for prescription drug monitoring programs that include data on prescriptions for medication assisted treatments for substance use disorders and opioid overdose reversal agents; (3) identify potential barriers to implementation of such guidelines and develop recommendations for addressing such barriers (such as development of standard data elements to be included in proactive or unsolicited reports or whether data on prescriptions for medication assisted treatments for substance use disorders and opioid overdose reversal agents should be included in prescription drug monitoring programs)